カテゴリー： Market Monitor Global, 世界, 医療/バイオ

ポックスウイルス科感染症治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Poxviridae Infections Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23LY8590）◆商品コード：MMG23LY8590
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年7月
◆ページ数：77
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Poxviridae Infections Drug Market 調査レポートは次の情報を含め、グローバルにおけるのポックスウイルス科感染症治療薬市場規模と予測を収録しています。・世界のポックスウイルス科感染症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界のポックスウイルス科感染症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のポックスウイルス科感染症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「CJ-40011」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

ポックスウイルス科感染症治療薬のグローバル主要企業は、Bavarian Nordic A/S、 BioFactura, Inc.、 CEL-SCI Corporation、 Chimerix, Inc.、 China Biologic Products, Inc.、 CJ HealthCare Corp.、 EpiVax, Inc.、 N & N Pharmaceuticals Inc.、 SIGA Technologies, Inc.、 Takeda Pharmaceutical Company Limited、 Tonix Pharmaceuticals Holding Corp.、 Verrica Pharmaceuticals Inc.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、ポックスウイルス科感染症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のポックスウイルス科感染症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界のポックスウイルス科感染症治療薬市場：タイプ別市場シェア、2022年
・CJ-40011、24a、BA-368、その他

世界のポックスウイルス科感染症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界のポックスウイルス科感染症治療薬市場：用途別市場シェア、2022年
・病院、診療所、その他

世界のポックスウイルス科感染症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界のポックスウイルス科感染症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるポックスウイルス科感染症治療薬のグローバル売上、2018年-2023年
・主要企業におけるポックスウイルス科感染症治療薬のグローバル売上シェア、2022年
・主要企業におけるポックスウイルス科感染症治療薬のグローバル販売量、2018年-2023年
・主要企業におけるポックスウイルス科感染症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Bavarian Nordic A/S、 BioFactura, Inc.、 CEL-SCI Corporation、 Chimerix, Inc.、 China Biologic Products, Inc.、 CJ HealthCare Corp.、 EpiVax, Inc.、 N & N Pharmaceuticals Inc.、 SIGA Technologies, Inc.、 Takeda Pharmaceutical Company Limited、 Tonix Pharmaceuticals Holding Corp.、 Verrica Pharmaceuticals Inc.

*************************************************************

・調査・分析レポートの概要
ポックスウイルス科感染症治療薬市場の定義
市場セグメント
世界のポックスウイルス科感染症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のポックスウイルス科感染症治療薬市場規模
世界のポックスウイルス科感染症治療薬市場規模：2022年 VS 2029年
世界のポックスウイルス科感染症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのポックスウイルス科感染症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のポックスウイルス科感染症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：CJ-40011、24a、BA-368、その他
ポックスウイルス科感染症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
ポックスウイルス科感染症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別ポックスウイルス科感染症治療薬市場規模 2022年と2029年
地域別ポックスウイルス科感染症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Bavarian Nordic A/S、 BioFactura, Inc.、 CEL-SCI Corporation、 Chimerix, Inc.、 China Biologic Products, Inc.、 CJ HealthCare Corp.、 EpiVax, Inc.、 N & N Pharmaceuticals Inc.、 SIGA Technologies, Inc.、 Takeda Pharmaceutical Company Limited、 Tonix Pharmaceuticals Holding Corp.、 Verrica Pharmaceuticals Inc.
...

This report aims to provide a comprehensive presentation of the global market for Poxviridae Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Poxviridae Infections Drug. This report contains market size and forecasts of Poxviridae Infections Drug in global, including the following market information:
Global Poxviridae Infections Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Poxviridae Infections Drug Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Poxviridae Infections Drug companies in 2022 (%)
The global Poxviridae Infections Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
CJ-40011 Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Poxviridae Infections Drug include Bavarian Nordic A/S, BioFactura, Inc., CEL-SCI Corporation, Chimerix, Inc., China Biologic Products, Inc., CJ HealthCare Corp., EpiVax, Inc., N & N Pharmaceuticals Inc. and SIGA Technologies, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Poxviridae Infections Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Poxviridae Infections Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Poxviridae Infections Drug Market Segment Percentages, by Type, 2022 (%)
CJ-40011
24a
BA-368
Others
Global Poxviridae Infections Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Poxviridae Infections Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Poxviridae Infections Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Poxviridae Infections Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Poxviridae Infections Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Poxviridae Infections Drug revenues share in global market, 2022 (%)
Key companies Poxviridae Infections Drug sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Poxviridae Infections Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
China Biologic Products, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
N & N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Poxviridae Infections Drug, market overview.
Chapter 2: Global Poxviridae Infections Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Poxviridae Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Poxviridae Infections Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Poxviridae Infections Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Poxviridae Infections Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Poxviridae Infections Drug Overall Market Size
2.1 Global Poxviridae Infections Drug Market Size: 2022 VS 2029
2.2 Global Poxviridae Infections Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Poxviridae Infections Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Poxviridae Infections Drug Players in Global Market
3.2 Top Global Poxviridae Infections Drug Companies Ranked by Revenue
3.3 Global Poxviridae Infections Drug Revenue by Companies
3.4 Global Poxviridae Infections Drug Sales by Companies
3.5 Global Poxviridae Infections Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Poxviridae Infections Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Poxviridae Infections Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Poxviridae Infections Drug Players in Global Market
3.8.1 List of Global Tier 1 Poxviridae Infections Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Poxviridae Infections Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Poxviridae Infections Drug Market Size Markets, 2022 & 2029
4.1.2 CJ-40011
4.1.3 24a
4.1.4 BA-368
4.1.5 Others
4.2 By Type – Global Poxviridae Infections Drug Revenue & Forecasts
4.2.1 By Type – Global Poxviridae Infections Drug Revenue, 2018-2023
4.2.2 By Type – Global Poxviridae Infections Drug Revenue, 2024-2029
4.2.3 By Type – Global Poxviridae Infections Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Poxviridae Infections Drug Sales & Forecasts
4.3.1 By Type – Global Poxviridae Infections Drug Sales, 2018-2023
4.3.2 By Type – Global Poxviridae Infections Drug Sales, 2024-2029
4.3.3 By Type – Global Poxviridae Infections Drug Sales Market Share, 2018-2029
4.4 By Type – Global Poxviridae Infections Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Poxviridae Infections Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Poxviridae Infections Drug Revenue & Forecasts
5.2.1 By Application – Global Poxviridae Infections Drug Revenue, 2018-2023
5.2.2 By Application – Global Poxviridae Infections Drug Revenue, 2024-2029
5.2.3 By Application – Global Poxviridae Infections Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Poxviridae Infections Drug Sales & Forecasts
5.3.1 By Application – Global Poxviridae Infections Drug Sales, 2018-2023
5.3.2 By Application – Global Poxviridae Infections Drug Sales, 2024-2029
5.3.3 By Application – Global Poxviridae Infections Drug Sales Market Share, 2018-2029
5.4 By Application – Global Poxviridae Infections Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Poxviridae Infections Drug Market Size, 2022 & 2029
6.2 By Region – Global Poxviridae Infections Drug Revenue & Forecasts
6.2.1 By Region – Global Poxviridae Infections Drug Revenue, 2018-2023
6.2.2 By Region – Global Poxviridae Infections Drug Revenue, 2024-2029
6.2.3 By Region – Global Poxviridae Infections Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Poxviridae Infections Drug Sales & Forecasts
6.3.1 By Region – Global Poxviridae Infections Drug Sales, 2018-2023
6.3.2 By Region – Global Poxviridae Infections Drug Sales, 2024-2029
6.3.3 By Region – Global Poxviridae Infections Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Poxviridae Infections Drug Revenue, 2018-2029
6.4.2 By Country – North America Poxviridae Infections Drug Sales, 2018-2029
6.4.3 US Poxviridae Infections Drug Market Size, 2018-2029
6.4.4 Canada Poxviridae Infections Drug Market Size, 2018-2029
6.4.5 Mexico Poxviridae Infections Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Poxviridae Infections Drug Revenue, 2018-2029
6.5.2 By Country – Europe Poxviridae Infections Drug Sales, 2018-2029
6.5.3 Germany Poxviridae Infections Drug Market Size, 2018-2029
6.5.4 France Poxviridae Infections Drug Market Size, 2018-2029
6.5.5 U.K. Poxviridae Infections Drug Market Size, 2018-2029
6.5.6 Italy Poxviridae Infections Drug Market Size, 2018-2029
6.5.7 Russia Poxviridae Infections Drug Market Size, 2018-2029
6.5.8 Nordic Countries Poxviridae Infections Drug Market Size, 2018-2029
6.5.9 Benelux Poxviridae Infections Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Poxviridae Infections Drug Revenue, 2018-2029
6.6.2 By Region – Asia Poxviridae Infections Drug Sales, 2018-2029
6.6.3 China Poxviridae Infections Drug Market Size, 2018-2029
6.6.4 Japan Poxviridae Infections Drug Market Size, 2018-2029
6.6.5 South Korea Poxviridae Infections Drug Market Size, 2018-2029
6.6.6 Southeast Asia Poxviridae Infections Drug Market Size, 2018-2029
6.6.7 India Poxviridae Infections Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Poxviridae Infections Drug Revenue, 2018-2029
6.7.2 By Country – South America Poxviridae Infections Drug Sales, 2018-2029
6.7.3 Brazil Poxviridae Infections Drug Market Size, 2018-2029
6.7.4 Argentina Poxviridae Infections Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Poxviridae Infections Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Poxviridae Infections Drug Sales, 2018-2029
6.8.3 Turkey Poxviridae Infections Drug Market Size, 2018-2029
6.8.4 Israel Poxviridae Infections Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Poxviridae Infections Drug Market Size, 2018-2029
6.8.6 UAE Poxviridae Infections Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bavarian Nordic A/S
7.1.1 Bavarian Nordic A/S Company Summary
7.1.2 Bavarian Nordic A/S Business Overview
7.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Major Product Offerings
7.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.1.5 Bavarian Nordic A/S Key News & Latest Developments
7.2 BioFactura, Inc.
7.2.1 BioFactura, Inc. Company Summary
7.2.2 BioFactura, Inc. Business Overview
7.2.3 BioFactura, Inc. Poxviridae Infections Drug Major Product Offerings
7.2.4 BioFactura, Inc. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.2.5 BioFactura, Inc. Key News & Latest Developments
7.3 CEL-SCI Corporation
7.3.1 CEL-SCI Corporation Company Summary
7.3.2 CEL-SCI Corporation Business Overview
7.3.3 CEL-SCI Corporation Poxviridae Infections Drug Major Product Offerings
7.3.4 CEL-SCI Corporation Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.3.5 CEL-SCI Corporation Key News & Latest Developments
7.4 Chimerix, Inc.
7.4.1 Chimerix, Inc. Company Summary
7.4.2 Chimerix, Inc. Business Overview
7.4.3 Chimerix, Inc. Poxviridae Infections Drug Major Product Offerings
7.4.4 Chimerix, Inc. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.4.5 Chimerix, Inc. Key News & Latest Developments
7.5 China Biologic Products, Inc.
7.5.1 China Biologic Products, Inc. Company Summary
7.5.2 China Biologic Products, Inc. Business Overview
7.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Major Product Offerings
7.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.5.5 China Biologic Products, Inc. Key News & Latest Developments
7.6 CJ HealthCare Corp.
7.6.1 CJ HealthCare Corp. Company Summary
7.6.2 CJ HealthCare Corp. Business Overview
7.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Major Product Offerings
7.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.6.5 CJ HealthCare Corp. Key News & Latest Developments
7.7 EpiVax, Inc.
7.7.1 EpiVax, Inc. Company Summary
7.7.2 EpiVax, Inc. Business Overview
7.7.3 EpiVax, Inc. Poxviridae Infections Drug Major Product Offerings
7.7.4 EpiVax, Inc. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.7.5 EpiVax, Inc. Key News & Latest Developments
7.8 N & N Pharmaceuticals Inc.
7.8.1 N & N Pharmaceuticals Inc. Company Summary
7.8.2 N & N Pharmaceuticals Inc. Business Overview
7.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Major Product Offerings
7.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.8.5 N & N Pharmaceuticals Inc. Key News & Latest Developments
7.9 SIGA Technologies, Inc.
7.9.1 SIGA Technologies, Inc. Company Summary
7.9.2 SIGA Technologies, Inc. Business Overview
7.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Major Product Offerings
7.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.9.5 SIGA Technologies, Inc. Key News & Latest Developments
7.10 Takeda Pharmaceutical Company Limited
7.10.1 Takeda Pharmaceutical Company Limited Company Summary
7.10.2 Takeda Pharmaceutical Company Limited Business Overview
7.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Major Product Offerings
7.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.10.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
7.11 Tonix Pharmaceuticals Holding Corp.
7.11.1 Tonix Pharmaceuticals Holding Corp. Company Summary
7.11.2 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Business Overview
7.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Major Product Offerings
7.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.11.5 Tonix Pharmaceuticals Holding Corp. Key News & Latest Developments
7.12 Verrica Pharmaceuticals Inc.
7.12.1 Verrica Pharmaceuticals Inc. Company Summary
7.12.2 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Business Overview
7.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Major Product Offerings
7.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales and Revenue in Global (2018-2023)
7.12.5 Verrica Pharmaceuticals Inc. Key News & Latest Developments
8 Global Poxviridae Infections Drug Production Capacity, Analysis
8.1 Global Poxviridae Infections Drug Production Capacity, 2018-2029
8.2 Poxviridae Infections Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Poxviridae Infections Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Poxviridae Infections Drug Supply Chain Analysis
10.1 Poxviridae Infections Drug Industry Value Chain
10.2 Poxviridae Infections Drug Upstream Market
10.3 Poxviridae Infections Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Poxviridae Infections Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Poxviridae Infections Drug in Global Market
Table 2. Top Poxviridae Infections Drug Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Poxviridae Infections Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Poxviridae Infections Drug Revenue Share by Companies, 2018-2023
Table 5. Global Poxviridae Infections Drug Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Poxviridae Infections Drug Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Poxviridae Infections Drug Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Poxviridae Infections Drug Product Type
Table 9. List of Global Tier 1 Poxviridae Infections Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Poxviridae Infections Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Poxviridae Infections Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Poxviridae Infections Drug Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Poxviridae Infections Drug Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Poxviridae Infections Drug Sales (K Pcs), 2018-2023
Table 15. By Type - Global Poxviridae Infections Drug Sales (K Pcs), 2024-2029
Table 16. By Application – Global Poxviridae Infections Drug Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Poxviridae Infections Drug Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Poxviridae Infections Drug Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Poxviridae Infections Drug Sales (K Pcs), 2018-2023
Table 20. By Application - Global Poxviridae Infections Drug Sales (K Pcs), 2024-2029
Table 21. By Region – Global Poxviridae Infections Drug Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Poxviridae Infections Drug Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Poxviridae Infections Drug Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Poxviridae Infections Drug Sales (K Pcs), 2018-2023
Table 25. By Region - Global Poxviridae Infections Drug Sales (K Pcs), 2024-2029
Table 26. By Country - North America Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Poxviridae Infections Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Poxviridae Infections Drug Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Poxviridae Infections Drug Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Poxviridae Infections Drug Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Poxviridae Infections Drug Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Poxviridae Infections Drug Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Poxviridae Infections Drug Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Poxviridae Infections Drug Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Poxviridae Infections Drug Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Poxviridae Infections Drug Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Poxviridae Infections Drug Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Poxviridae Infections Drug Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Poxviridae Infections Drug Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Poxviridae Infections Drug Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Poxviridae Infections Drug Sales, (K Pcs), 2024-2029
Table 46. Bavarian Nordic A/S Company Summary
Table 47. Bavarian Nordic A/S Poxviridae Infections Drug Product Offerings
Table 48. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Bavarian Nordic A/S Key News & Latest Developments
Table 50. BioFactura, Inc. Company Summary
Table 51. BioFactura, Inc. Poxviridae Infections Drug Product Offerings
Table 52. BioFactura, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. BioFactura, Inc. Key News & Latest Developments
Table 54. CEL-SCI Corporation Company Summary
Table 55. CEL-SCI Corporation Poxviridae Infections Drug Product Offerings
Table 56. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. CEL-SCI Corporation Key News & Latest Developments
Table 58. Chimerix, Inc. Company Summary
Table 59. Chimerix, Inc. Poxviridae Infections Drug Product Offerings
Table 60. Chimerix, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Chimerix, Inc. Key News & Latest Developments
Table 62. China Biologic Products, Inc. Company Summary
Table 63. China Biologic Products, Inc. Poxviridae Infections Drug Product Offerings
Table 64. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. China Biologic Products, Inc. Key News & Latest Developments
Table 66. CJ HealthCare Corp. Company Summary
Table 67. CJ HealthCare Corp. Poxviridae Infections Drug Product Offerings
Table 68. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. CJ HealthCare Corp. Key News & Latest Developments
Table 70. EpiVax, Inc. Company Summary
Table 71. EpiVax, Inc. Poxviridae Infections Drug Product Offerings
Table 72. EpiVax, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. EpiVax, Inc. Key News & Latest Developments
Table 74. N & N Pharmaceuticals Inc. Company Summary
Table 75. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Offerings
Table 76. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. N & N Pharmaceuticals Inc. Key News & Latest Developments
Table 78. SIGA Technologies, Inc. Company Summary
Table 79. SIGA Technologies, Inc. Poxviridae Infections Drug Product Offerings
Table 80. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. SIGA Technologies, Inc. Key News & Latest Developments
Table 82. Takeda Pharmaceutical Company Limited Company Summary
Table 83. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Offerings
Table 84. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. Takeda Pharmaceutical Company Limited Key News & Latest Developments
Table 86. Tonix Pharmaceuticals Holding Corp. Company Summary
Table 87. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Offerings
Table 88. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. Tonix Pharmaceuticals Holding Corp. Key News & Latest Developments
Table 90. Verrica Pharmaceuticals Inc. Company Summary
Table 91. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Offerings
Table 92. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. Verrica Pharmaceuticals Inc. Key News & Latest Developments
Table 94. Poxviridae Infections Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 95. Global Poxviridae Infections Drug Capacity Market Share of Key Manufacturers, 2021-2023
Table 96. Global Poxviridae Infections Drug Production by Region, 2018-2023 (K Pcs)
Table 97. Global Poxviridae Infections Drug Production by Region, 2024-2029 (K Pcs)
Table 98. Poxviridae Infections Drug Market Opportunities & Trends in Global Market
Table 99. Poxviridae Infections Drug Market Drivers in Global Market
Table 100. Poxviridae Infections Drug Market Restraints in Global Market
Table 101. Poxviridae Infections Drug Raw Materials
Table 102. Poxviridae Infections Drug Raw Materials Suppliers in Global Market
Table 103. Typical Poxviridae Infections Drug Downstream
Table 104. Poxviridae Infections Drug Downstream Clients in Global Market
Table 105. Poxviridae Infections Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Poxviridae Infections Drug Segment by Type in 2022
Figure 2. Poxviridae Infections Drug Segment by Application in 2022
Figure 3. Global Poxviridae Infections Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Poxviridae Infections Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Poxviridae Infections Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. Poxviridae Infections Drug Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Poxviridae Infections Drug Revenue in 2022
Figure 9. By Type - Global Poxviridae Infections Drug Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 11. By Type - Global Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 12. By Type - Global Poxviridae Infections Drug Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Poxviridae Infections Drug Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 15. By Application - Global Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 16. By Application - Global Poxviridae Infections Drug Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Poxviridae Infections Drug Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Poxviridae Infections Drug Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 20. By Region - Global Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 21. By Country - North America Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 22. By Country - North America Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 23. US Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 28. Germany Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 29. France Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 37. China Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 41. India Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 43. By Country - South America Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 44. Brazil Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Poxviridae Infections Drug Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Poxviridae Infections Drug Sales Market Share, 2018-2029
Figure 48. Turkey Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Poxviridae Infections Drug Revenue, (US$, Mn), 2018-2029
Figure 52. Global Poxviridae Infections Drug Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Poxviridae Infections Drug by Region, 2022 VS 2029
Figure 54. Poxviridae Infections Drug Industry Value Chain
Figure 55. Marketing Channels


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ ポックスウイルス科感染症治療薬の世界市場見通し2023年-2029年(Poxviridae Infections Drug Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

※関連リサーチレポートはありません。


◆H&Iグローバルリサーチのお客様（例）◆